Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas

European Journal of Cancer

Volumn 42, Issue 15, 2006, Pages 2631-2638

  Ulisse, S ^a   Baldini, E ^a   Toller, M ^b   Marchioni, E ^c   Giacomelli, L ^c   De Antoni, E ^c   Ferretti, E ^c   Marzullo, A ^c   Graziano, F M ^c   Trimboli, P ^c   Biordi, L ^a   Curcio, F ^b   Gulino, A ^c   Ambesi Impiombato, F S ^b   D'Armiento, M ^c  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Human; Plasminogen activator inhibitors; Plasminogen activators; Thyrocyte; Thyroid tumours; Urokinase plasminogen activator receptor

Indexed keywords

MESSENGER RNA; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; CARCINOMA CELL; ENZYME ACTIVITY; FOLLICULAR CARCINOMA; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; PAPILLARY CARCINOMA; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID CANCER; THYROID CELL; THYROID TUMOR; TUMOR CELL LINE; TUMOR VOLUME; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, PAPILLARY; CELL LINE, TUMOR; HUMANS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PLASMINOGEN ACTIVATORS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; THYROID NEOPLASMS; URINARY PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 33749153201     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.04.017     Document Type: Article

References (39)

1. Collen D. The plasminogen (fibrinolytic) system. Thromb Haemost 82 (1999) 259-270
2. Andreasen P.A., Kjoller L., Christensen L., and Duffy M.J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72 (1997) 1-2
3. Duffy M.J. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 10 (2004) 39-49
4. Visse R., and Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res 92 (2003) 827-839
5. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 10 (2000) 415-433
6. Blasi F., and Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 3 (2002) 932-943
7. Choong P.F.M., and Nadesapillai A.P.W. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin Orthop Relat Res 415S (2003) S46-S58
8. Pepper M.S. Role of matrix metalloproteinases and plasminogen activator-plasmin system in angiogenesis. Arterioscler Thromb Vasc Biol 21 (2001) 1104-1117
9. de Bock C.E., and Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev 24 (2004) 13-19
10. Duffy M.J. Urokinase plasminogen activator and its inhibitor PAI-1 as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem 48 (2002) 1194-1197
11. Esteva F.J., and Hortobagyi G.N. Prognostic molecular markers in early breast cancer. Breast Cancer Res 6 (2004) 109-118
12. Schmitt M., Harbeck N., Thomssen C., et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 78 (1997) 285-296
13. Duffy M.J. Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancer. Biochem Soc Trans 30 (2002) 207-210
14. Look M.P., van Putten W.L., Duffy M.J., et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94 (2002) 116-128
15. Rockway T.W., Nienaber V., and Giranda V.L. Inhibitors of protease domain of urokinase-type plasminogen activator. Curr Pharm Des 8 (2002) 2541-2558
16. Xing R.H., Mazar A., Henkin J., and Rabbani S.A. Prevention of breast cancer growth, invasion and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. Cancer Res 57 (1997) 3585-3593
17. Rabbani S.A., Harakidas P., Davidson D.J., Henkin J., and Mazar A.P. Prevention of prostate cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int J Cancer 63 (1995) 840-845
18. Ossowsky L., and Reich E. Antibodies to plasminogen activator inhibits human tumor metastasis. Cell 35 (1983) 611-619
19. Ramsden J.D., Yarram S., Mathews E., Watkinson J.C., and Eggo M.C. Thyroid follicular cells secrete plasminogen activators and can form angiostatin from plasminogen. J Endocrinol 173 (2002) 475-481
20. Ragno P., Montuori N., Salzano S., and Rossi G. Urokinase-type plasminogen-activator and normal thyroid cell adhesion to the extracellular matrix. Biochimie 81 (1999) 355-358
21. Montuori N., Rossi G., and Ragno P. Cleavage of urokinase receptor regulates its interaction with integrins in thyroid cells. FEBS Lett 460 (1999) 32-36
22. Montuori N., Salzano S., Rossi G., and Ragno P. Urokinase-type plasminogen activator up-regulates the expression of its cellular receptor. FEBS Lett 476 (2000) 166-170
23. Ito Y., Takeda T., Kobayashi T., et al. Plasminogen activation system in active even in thyroid tumors; an immunohistochemical study. Anticancer Res 16 (1996) 81-89
24. Packman K.S., Demeure M.J., Doffek K.M., and Wilson S.D. Increased plasminogen activator and type IV collagenase activity in invasive follicular thyroid carcinoma cells. Surgery 118 (1995) 1011-1016
25. Kim S.J., Shiba E., Taguchi T., et al. uPA receptor expression in benign and malignant thyroid tumors. Anticancer Res 22 (2002) 387-393
26. Zanetti A., Stoppacciaro A., Marzullo A., et al. Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid. J Pathol 186 (1998) 287-291
27. Smith J.W., van der Pluijm G., Romijn H.A., Lowik C.W., Morreau H., et al. Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system. Thyroid 9 (1999) 913-919
28. Gioanni J., Zanghellini E., Mazeau C., et al. Characterization of a human cell line from an anaplastic carcinoma of the thyroid gland. Bull Cancer 78 (1991) 1053-1062
29. Smanik P.A., Fithian L.J., and Jhiang S.M. Thyroid peroxidase expression and DNA polymorphisms in thyroid cancer. Biochem Biophys Res Commun 198 (1994) 948-954
30. Fabien N., Fusco A., Santoro M., Barbier Y., Dubois P.M., et al. Description of a human papillary thyroid carcinoma cell line. Morphologic study and expression of tumoral markers. Cancer 73 (1994) 2206-2212
31. Bajou K., Lewalle J.M., Martinez C.R., et al. Human breast adenocarcinoma cell lines promote angiogenesis by providing cells with uPA-PAI-1 and by enhancing their expression. Int J Cancer 100 (2002) 501-506
32. Curcio F., Ambesi-Impiombato F.S., Perrella G., and Coon H.G. Long-term culture and functional characterization of follicular cells from adult normal human thyroids. Proc Natl Acad Sci USA 91 (1994) 9004-9008
33. Perrella G., Fabbro D., Damante G., et al. Expression of differentiation markers in cultured cells from various thyroid diseases. Thyroid 7 (1997) 817-821
34. Trusolino L., Serini G., Cecchini G., et al. Growth factor-dependent activation of αvβ3 integrin in normal epithelial cells: implications for tumor invasion. J Cell Biol 142 (1998) 1145-1156
35. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
36. Ulisse S., Rucci N., Piersanti D., et al. Regulation by thyroid hormone of the expression of basement membrane components in rat prepubertal Sertoli cells. Endocrinology 139 (1998) 741-747
37. Chomczynsky P., and Sacchi P. Single step method of RNA isolation by guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162 (1987) 156-159
38. Baldini E., Toller M., Graziano F.M., et al. Expression of matrix metalloproteinases and their specific inhibitors (TIMPs) in normal and different human thyroid tumor cell lines. Thyroid 14 (2004) 881-888
39. Gospodarowicz M.K., Henson D.E., Hutter R.V.P., O'Sullivan B., Sobin L.H., et al. Prognostic factors in cancer. 2nd ed. UICC (2002), Wiley-Liss, New York